Retatrutide, developed by Soma, represents a exciting advance in body regulation. This check here dual-action medication combines GLP-1 receptor activity with GIP receptor agonist stimulation , indicating remarkable results in trial data for weight loss . Experts believe this treatment could offer a different option for individuals struggling with